1
|
Sarnat HB, Chan ES, Ng D, Yu W. Maturation of metastases in peripheral neuroblastic tumors (neuroblastoma) of children. J Neuropathol Exp Neurol 2023; 82:853-864. [PMID: 37682248 DOI: 10.1093/jnen/nlad068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2023] Open
Abstract
Peripheral neuroblastic tumors of childhood exhibit 3 principal neural crest lineages: primitive neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. They are unique in undergoing maturation of neurons (ganglion cells) and Schwann cells, thereby recapitulating normal fetal neuronal development in the brain. Precision in estimating neurogenesis is enhanced by immunoreactivities of markers of neuronal maturation. Whether organ tissue factors in different sites of metastases influence rates of maturation and whether metastases are similar to their primary neuroblastic tumor are incompletely documented. Four young children, 1 with a mixed primary adrenal tumor and 3 with metastases were studied at surgery or autopsy. Immunocytochemical reactivities included microtubule-associated protein-2, synaptophysin, chromogranin-A, somatostatin, keratan sulfate, vimentin, S-100β protein, and PHOX2B. Primary tumors were non-uniform with regions of either poor or enhanced maturation. Both neuronal and Schwannian lineages were represented in each tumor type but differed in proportions. Bi- or multi-nucleated ganglion cells matured equal to mononuclear forms. Ganglion cell maturation was similar in metastases regardless of the target organ. Metastases resembled primary tumors. Immunocytochemical markers of neuronal and of Schwann cell maturation provide greater diagnostic precision to supplement histological criteria. Interval between diagnosis of primary tumor and metastases, metastatic target tissues, and chemotherapy over an interval of time do not appear to influence neuroblastic or Schwann cell differentiation.
Collapse
Affiliation(s)
- Harvey B Sarnat
- Department of Paediatrics, University of Calgary Cumming School of Medicine and Alberta Children's Hospital Research Institute (Owerko Centre), Calgary, Alberta, Canada
- Department of Pathology and Laboratory Medicine (Neuropathology), University of Calgary Cumming School of Medicine and Alberta Children's Hospital Research Institute (Owerko Centre), Calgary, Alberta, Canada
- Department of Clinical Neurosciences, University of Calgary Cumming School of Medicine and Alberta Children's Hospital Research Institute (Owerko Centre), Calgary, Alberta, Canada
| | - Elaine S Chan
- Department of Pathology and Laboratory Medicine (Paediatric Anatomical Pathology), University of Calgary Cumming School of Medicine and Alberta Children's Hospital Research Institute (Owerko Centre), Calgary, Alberta, Canada
| | - Denise Ng
- Department of Pathology and Laboratory Medicine (Neuropathology), University of Calgary Cumming School of Medicine and Alberta Children's Hospital Research Institute (Owerko Centre), Calgary, Alberta, Canada
| | - Weiming Yu
- Department of Pathology and Laboratory Medicine (Paediatric Anatomical Pathology), University of Calgary Cumming School of Medicine and Alberta Children's Hospital Research Institute (Owerko Centre), Calgary, Alberta, Canada
| |
Collapse
|
2
|
Pang K, Guo X, Jiang Y, Xu L, Ling L, Li Z. Case Report: Primary Intraosseous Poorly Differentiated Synovial Sarcoma of the Femur. Front Oncol 2022; 12:754131. [PMID: 35372059 PMCID: PMC8966429 DOI: 10.3389/fonc.2022.754131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 02/09/2022] [Indexed: 01/24/2023] Open
Abstract
Primary intraosseous poorly differentiated synovial sarcoma is exceedingly rare. Here, we present a case of primary intraosseous poorly differentiated synovial sarcoma from the proximal femur in a 16-year-old girl. The case was initially misdiagnosed, but the correct diagnosis of synovial sarcoma was eventually confirmed by fluorescence in situ hybridization and next-generation sequencing. We review the literature pertaining to synovial sarcoma and show that this case is the second molecularly proven intraosseous poorly differentiated synovial sarcoma in the literature. Recognition of intraosseous synovial sarcoma composed of small round cells is imperative in order to avoid misdiagnosis of the tumor as Ewing sarcoma and other small round-cell tumors, all of which have markedly different clinical management.
Collapse
Affiliation(s)
- Ke Pang
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, China,Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Xiaoning Guo
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yi Jiang
- Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Lina Xu
- Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Lin Ling
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, China,*Correspondence: Lin Ling, ; Zhihong Li,
| | - Zhihong Li
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, China,Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, China,*Correspondence: Lin Ling, ; Zhihong Li,
| |
Collapse
|
3
|
Barroca H. Pediatric Small Round Blue Cell Tumors: Cytopathological Puzzle or an Intriguing Scientific Window? Acta Cytol 2021; 66:319-335. [PMID: 34289477 DOI: 10.1159/000517167] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Accepted: 04/29/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND Small round blue cell tumors or more commonly called small round cell tumors (SRCTs) are undifferentiated neoplasms, sharing an overlapping morphological pattern of small round blue cells. Diagnosing these tumors represents a complex challenge for cytopathologists and for general surgical pathologist alike. This stems from the fact that these tumors share not only similar morphological features, but also some immunophenotypic characteristics, thus requiring a broad panel of antibodies, which might not be included in the most basic immunohistochemistry panels, used in the routine work of most pathology laboratories. Furthermore, one should note that the diagnosis, prognosis, and/or therapeutic decision are often dependent on the knowledge of the existence of specific molecular alterations, which requires access to sophisticated molecular ancillary techniques. Cytological diagnosis of SRCT should be systematized. A thorough understanding of the morphological pattern of these tumors, the small details they entail, the background and cellular patterns, and the nuclear and cytoplasmic peculiarities, may hint to the most probable diagnosis. Minor clues, such as the presence of a fibrillar background, the presence of rosettes or a specific "salt and pepper" chromatin, are important clues toward a probable diagnosis of a neuroblastoma, or the presence of a tigroid background is a characteristic of rhabdomyosarcoma and the Ewing family tumors. However, in poorly differentiated tumors, morphology alone will not suffice, making it essential for the access to complementary diagnostic techniques in order to reach the final diagnosis. Summary and Key Messages: The cytological diagnosis and treatment of SRCTs require an experienced, well-articulated, proficient teamwork, and sophisticated complementary diagnostic techniques, only available in centers of reference.
Collapse
Affiliation(s)
- Helena Barroca
- Serviço de Anatomia Patológica, Centro Hospitalar de S João, Porto, Portugal
| |
Collapse
|
4
|
Botiralieva GK, Sharlai AS, Roshchin VY, Sidorov IV, Konovalov DM. [Rhabdomyosarcomas: structural distribution and analysis of an immunohistochemical profile]. Arkh Patol 2020; 82:33-41. [PMID: 33054030 DOI: 10.17116/patol20208205133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Rhabdomyosarcoma (RMS) is a malignant soft tissue tumor originating from primitive mesenchymal cells, which is most common in children. OBJECTIVE To qualitatively and quantitatively assess the expression of myogenic transcription factors on a large sample, to identify potential phenotypic differences, and to estimate the distribution and frequency of aberrant markers, such as ALK, PAX5, WT1, PCK, CAM5.2, SIX1, and Synaptophysin. MATERIAL AND METHODS The investigation included 202 tumor tissue samples. Five tissue microarrays were assembled from the obtained material for subsequent histological and immunohistochemical studies. RESULTS Embryonal RMS (ERMS) was diagnosed in 103 cases; alveolar RMS (ARMS) was detected in 80; spindle-cell/sclerosing RMS (SRMS) was found in 16 cases; epithelioid RMS (EpiRMS) was diagnosed in 2 patients. The expression of Myogenin and MyoD1 was detected in all the examined RMS tissue samples. ARMS was more characterized by staining at 1+ and 2+ intensities; at the same time, more than 50% of ERMS, SRMS, and EpiRMS cases showed staining at 1+ intensity. ALK expression was investigated using the D5F3 and p80 clones. The D5F3 clone displayed a higher staining intensity than the p80 clone (p<0.05). The expression of PAX5 was observed in 13 of 75 ARMS cases. That of WT1 and SIX1 was found in all RMS groups. CONCLUSION The morphological diagnosis of RMS requires a careful assessment of all of the above factors, especially taking into account the variability in the expression of myogenic transcription factors and the high level of phenotypic aberration.
Collapse
Affiliation(s)
| | - A S Sharlai
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia
| | - V Yu Roshchin
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia
| | - I V Sidorov
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia
| | - D M Konovalov
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.,Russian Medical Academy for Continuous Professional Education, Moscow, Russia
| |
Collapse
|
5
|
Yoshioka S, Ebisu Y, Ishida M, Miyasaka C, Taniguchi Y, Murakawa T, Tsuta K. Fine-needle aspiration cytology of primary mediastinal synovial sarcoma: A case report with an immunocytochemical approach. Diagn Cytopathol 2020; 48:499-501. [PMID: 32154674 DOI: 10.1002/dc.24407] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Revised: 02/09/2020] [Accepted: 02/26/2020] [Indexed: 11/06/2022]
Affiliation(s)
- Saya Yoshioka
- Department of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan
| | - Yusuke Ebisu
- Department of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan
| | - Mitsuaki Ishida
- Department of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan
| | - Chika Miyasaka
- Department of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan
| | - Yohei Taniguchi
- Department of Thoracic Surgery, Kansai Medical University, Osaka, Japan
| | - Tomohiro Murakawa
- Department of Thoracic Surgery, Kansai Medical University, Osaka, Japan
| | - Koji Tsuta
- Department of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan
| |
Collapse
|
6
|
Immunohistochemical Expression of Wilms’ Tumor 1 Protein in Human Tissues: From Ontogenesis to Neoplastic Tissues. APPLIED SCIENCES-BASEL 2019. [DOI: 10.3390/app10010040] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The human Wilms’ tumor gene (WT1) was originally isolated in a Wilms’ tumor of the kidney as a tumor suppressor gene. Numerous isoforms of WT1, by combination of alternative translational start sites, alternative RNA splicing and RNA editing, have been well documented. During human ontogenesis, according to the antibodies used, anti-C or N-terminus WT1 protein, nuclear expression can be frequently obtained in numerous tissues, including metanephric and mesonephric glomeruli, and mesothelial and sub-mesothelial cells, while cytoplasmic staining is usually found in developing smooth and skeletal cells, myocardium, glial cells, neuroblasts, adrenal cortical cells and the endothelial cells of blood vessels. WT1 has been originally described as a tumor suppressor gene in renal Wilms’ tumor, but more recent studies emphasized its potential oncogenic role in several neoplasia with a variable immunostaining pattern that can be exclusively nuclear, cytoplasmic or both, according to the antibodies used (anti-C or N-terminus WT1 protein). With the present review we focus on the immunohistochemical expression of WT1 in some tumors, emphasizing its potential diagnostic role and usefulness in differential diagnosis. In addition, we analyze the WT1 protein expression profile in human embryonal/fetal tissues in order to suggest a possible role in the development of organs and tissues and to establish whether expression in some tumors replicates that observed during the development of tissues from which these tumors arise.
Collapse
|
7
|
Santiago T, Hayes C, Polanco AC, Miranda L, Aybar A, Gomero B, Orellana E, Anglade F, Toledo González ML, Ruiz E, Espino-Durán M, Rodriguez-Galindo C, Metzger ML. Improving Immunohistochemistry Capability for Pediatric Cancer Care in the Central American and Caribbean Region: A Report From the AHOPCA Pathology Working Group. J Glob Oncol 2018; 4:1-9. [PMID: 30241256 PMCID: PMC6223474 DOI: 10.1200/jgo.17.00187] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Accessibility to immunohistochemistry (IHC) is invaluable to proper diagnosis and treatment of pediatric patients with malignant neoplasms. Whereas IHC is widely available in anatomic pathology laboratories in high-income countries, access to it in anatomic pathology laboratories of low- and middle-income countries remains a struggle, with many limitations. To advance the quality of the pathology service offered to children with cancer in areas with limited resources, a 5-day pathology training workshop was offered to pathologists and histotechnologists from various countries of the Central American and Caribbean region. An initial assessment of the workshop participants’ current laboratory capacities was performed, and a regional training center was selected. Didactic and hands-on activities were offered, and review and evaluation of the IHC slides produced during the training course were compared with original slides from the participants’ sites. This model of intensive 5-day training appears to be effective and can potentially be used in other budget-constrained regions. Moreover, it can serve as a continuing education activity for pathologists and histotechnologists, and as part of validations and quality improvement projects to build capacity and develop IHC assay proficiency in low- and middle-income countries.
Collapse
Affiliation(s)
- Teresa Santiago
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Caleb Hayes
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Ana Concepción Polanco
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Lisa Miranda
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Argelia Aybar
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Belkis Gomero
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Elizabeth Orellana
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Fabienne Anglade
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Mázlova Luxely Toledo González
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Eduviges Ruiz
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Moisés Espino-Durán
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Carlos Rodriguez-Galindo
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| | - Monika L Metzger
- Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo, and Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Ana Concepción Polanco, Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador; Lisa Miranda, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera," San José, Costa Rica; Argelia Aybar, MediPath, Santiago City; Belkis Gomero, Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic; Elizabeth Orellana, Francisco Marroquín Medical School, Guatemala City, Guatemala; Fabienne Anglade, Laboratory Regional Stephen at Pilar Robert, Mirebelais, Haiti; Mázlova Luxely Toledo González, Hospital Escuela-Universitario, Tegucigalpa, Honduras; Eduviges Ruiz, Hospital Infantil Manuel de Jesus Rivera "La Mascota," Managua, Nicaragua; Moisés Espino-Durán, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama
| |
Collapse
|
8
|
Rekhi B, Gupta C, Chinnaswamy G, Qureshi S, Vora T, Khanna N, Laskar S. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience. Ann Diagn Pathol 2018; 36:50-60. [PMID: 30098515 DOI: 10.1016/j.anndiagpath.2018.07.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 07/07/2018] [Accepted: 07/30/2018] [Indexed: 10/28/2022]
Abstract
The present study was aimed at evaluating clinicopathologic and immunohistochemical (IHC) features of 300 rhabdomyosarcomas (RMSs), including differential IHC expression and prognostic value of myogenin and MyoD1 across various subtypes of RMSs. IHC expression of myogenin and MyoD1 was graded on the basis of percentage of tumor cells displaying positive intranuclear immunostaining i.e. grade 1 (1-25%); grade 2 (26-50%); grade 3 (51-76%) and grade 4 (76-100%).Clinical follow-up was available in 238 (79.3%) patients. Various clinicopathologic parameters were correlated with 3-year disease free survival (DFS) and overall survival (OS). There were 140 cases (46.7%) of alveolar RMS (ARMS), 90 of embryonal RMS (ERMS) (30%), 61 (20.3%) of spindle cell/sclerosing RMS and 9 cases (3%) of pleomorphic RMS. Most cases, barring pleomorphic RMSs, occurred in the first two decades (228 cases) (76%), frequently in males, in the head and neck region (126) (42%). By immunohistochemistry, desmin was positive in 292/299 (97.6%) tumors; myogenin in 238/267 (89.1%) and MyoD1 in 192/266 (72.2%) tumors. High myogenin expression (in ≥51% positive tumor cells) was significantly associated with ARMSs (95/121, 78.5%), as compared to other subtypes (48/117, 41%) (p value < 0.001). High MyoD1 expression (≥51% tumor cells) was seen in more cases of pure sclerosing, combined with spindle cell/sclerosing RMSs (10/10, 100%), as compared to the other subtypes (91/141, 67.4%) (p = 0.032). There was no significant difference between high myogenin expression and clinical outcomes. Patients without metastasis and harbouring tumors, measuring ≤5 cm showed a significant increase in OS, with p values = 0.01 and <0.001, respectively. ARMS was the most frequent subtype. There was a significant association between high myogenin expression and ARMSs and high MyoD1 expression and spindle cell/sclerosing RMSs. High myogenin expression did not correlate with clinical outcomes. Patients with smaller sized tumors and without metastasis had significantly better clinical outcomes.
Collapse
Affiliation(s)
- Bharat Rekhi
- Department of Surgical Pathology, Tata Memorial Hospital, Maharashtra, Mumbai, India.
| | - Chhavi Gupta
- Department of Surgical Pathology, Tata Memorial Hospital, Maharashtra, Mumbai, India
| | - Girish Chinnaswamy
- Department of Medical Oncology, Tata Memorial Hospital, Maharashtra, Mumbai, India
| | - Sajid Qureshi
- Department of Surgical Oncology, Tata Memorial Hospital, Maharashtra, Mumbai, India
| | - Tushar Vora
- Department of Medical Oncology, Tata Memorial Hospital, Maharashtra, Mumbai, India
| | - Nehal Khanna
- Department of Radiation Oncology, Tata Memorial Hospital, Maharashtra, Mumbai, India
| | - Siddhartha Laskar
- Department of Radiation Oncology, Tata Memorial Hospital, Maharashtra, Mumbai, India
| |
Collapse
|
9
|
Adrenal mass of unusual etiology: Ewing sarcoma in a young man. Radiol Case Rep 2018; 12:838-844. [PMID: 29484083 PMCID: PMC5823311 DOI: 10.1016/j.radcr.2017.07.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2017] [Revised: 06/19/2017] [Accepted: 07/03/2017] [Indexed: 11/21/2022] Open
Abstract
Ewing sarcoma and peripheral primitive neuroectodermal tumor belong to the Ewing sarcoma (ES) family of tumors originating from a primitive neural tube. We report a 31-year-old man who was admitted to the urology clinic with complaints of fever, nausea, and dysuria. A right-sided adrenal mass was detected during ultrasonography. The lesion was then evaluated with magnetic resonance imaging, which showed areas of necrosis amid heterogeneous solid areas. Whole body scan with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography and bone scan studies showed pulmonary and osseous metastatic foci. The mass and right kidney were removed by an open approach. An immunohistochemical and molecular workup enabled the diagnosis of ES. The patient also underwent radiotherapy and chemotherapy. The patient remained in fairly good health during the 18-month follow-up period, but showed progression of all metastatic foci and died 26 months after treatment. In conclusion, adrenal ES should be included in the differential diagnosis of nonfunctional adrenal lesions despite its rare occurrence.
Collapse
|
10
|
Thompson LDR, Jo VY, Agaimy A, Llombart-Bosch A, Morales GN, Machado I, Flucke U, Wakely PE, Miettinen M, Bishop JA. Sinonasal Tract Alveolar Rhabdomyosarcoma in Adults: A Clinicopathologic and Immunophenotypic Study of Fifty-Two Cases with Emphasis on Epithelial Immunoreactivity. Head Neck Pathol 2017; 12:181-192. [PMID: 28875443 PMCID: PMC5953873 DOI: 10.1007/s12105-017-0851-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Accepted: 08/31/2017] [Indexed: 12/22/2022]
Abstract
Sinonasal tract (SNT) alveolar rhabdomyosarcoma (ARMS) are frequently misdiagnosed, especially in adults. Fifty-two adult (≥18 years) patients with SNT ARMS were reviewed and characterized by immunohistochemistry and molecular studies. Twenty-six females and 26 males (18-72 years; mean 43.2 years), presented after a short duration (mean 2.6 months) with a large (mean 5.5 cm) destructive nasal cavity mass, involving multiple contiguous paranasal sites (n = 46) and with cervical adenopathy (n = 41). The tumors showed an alveolar, nested to solid growth pattern below an intact, but often involved (n = 9) epithelium with frequent necrosis (n = 37), destructive bone invasion (n = 30), and lymphovascular invasion (n = 25). The neoplastic cells were dyshesive and dilapidated, with crush artifacts. Rhabdoid features (n = 36) and tumor cell multinucleation (n = 28) were common. Mitotic counts were high (mean 17/10 HPFs). The neoplastic cells showed the following immunohistochemical positive findings: desmin (100%), myogenin (100%), MYOD1 (100%), MSA (96%), SMA (52%), CAM5.2 (50%), AE1/AE3 (36%); other positive markers included S100 protein (27%), CD56 (100%), synaptophysin (35%), and chromogranin (13%). Overall, 54% show epithelial marker reactivity. Molecular studies showed FOXO1 translocations (81%) with PCR demonstrating PAX3 in 72.7% tested. Patients presented with high stage (IV 24; III 26) and metastatic disease (lymph nodes n = 41; distant metastases n = 25) (IRSG grouping). Surgery (n = 16), radiation (n = 41) and chemotherapy (n = 45) yielded an overall survival of 36.1 months (mean; range 2.4-286); 18 alive without disease (mean 69.6 months); 7 alive with disease (mean 11.0 months); 1 dead without disease (63.7 months); and 26 dead with disease (mean 18.5 months). SNT ARMS frequently present in adults as a large, destructive midline mass of short symptom duration, with high stage disease. The alveolar to solid pattern of growth of cells with rhabdoid-plasmacytoid features suggests the diagnosis, but epithelial immunohistochemistry markers are present in 54% of cases, leading to misdiagnosis as carcinomas if muscle markers are not also performed. Overall survival of 36.1 months is achieved with multimodality therapy, but 64% have incurable disease (16.9 months). Mixed anatomic site (p = 0.02) was a significant adverse prognostic indicator, while stage (0.06) and tumor size >5 cm (0.06) approached marginal significance.
Collapse
Affiliation(s)
- Lester D. R. Thompson
- 0000 0004 0445 0789grid.417224.6Southern California Permanente Medical Group, Department of Pathology, Woodland Hills Medical Center, 5601 De Soto Avenue, Woodland Hills, CA 91365 USA
| | - Vickie Y. Jo
- 0000 0004 0378 8294grid.62560.37Brigham and Women’s Hospital and Harvard Medical School, Boston, MA USA
| | - Abbas Agaimy
- 0000 0000 9935 6525grid.411668.cInstitute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital, Erlangen, Germany
| | | | | | - Isidro Machado
- 0000 0004 1771 144Xgrid.418082.7Instituto Valenciano de Oncología, Valencia, Spain
| | - Uta Flucke
- 0000 0004 0444 9382grid.10417.33Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
| | - Paul E. Wakely
- 0000 0001 1545 0811grid.412332.5The Ohio State University Wexner Medical Center, Columbus, OH USA
| | - Markku Miettinen
- 0000 0004 1936 8075grid.48336.3aNational Cancer Institute/National Institutes of Health, Bethesda, MD USA
| | - Justin A. Bishop
- Southwestern Medical Center, University of Texas, Dallas, TX USA
| |
Collapse
|
11
|
WT1 Alternative Splicing: Role of Its Isoforms in Neuroblastoma. J Mol Neurosci 2017; 62:131-141. [DOI: 10.1007/s12031-017-0930-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Accepted: 05/08/2017] [Indexed: 02/07/2023]
|
12
|
Maugeri G, D'Amico AG, Rasà DM, Reitano R, Saccone S, Federico C, Parenti R, Magro G, D'Agata V. Expression profile of Wilms Tumor 1 (WT1) isoforms in undifferentiated and all-trans retinoic acid differentiated neuroblastoma cells. Genes Cancer 2016; 7:47-58. [PMID: 27014421 PMCID: PMC4773705 DOI: 10.18632/genesandcancer.94] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Wilms tumor 1 gene (WT1) is a tumor suppressor gene originally identified in nephroblastoma. It is also expressed in neuroblastoma which represents the most aggressive extracranial pediatric tumor. Many evidences have shown that neuroblastoma may undergo maturation, by transforming itself in a more differentiated tumors such as ganglioneuroblastoma and ganglioneuroma, or progressing into a highly aggressive metastatic malignancy. To date, 13 WT1 mRNA alternative splice variants have been identified. However, most of the studies have focused their attention only on isoform of ∼49 kDa. In the present study, it has been investigated the expression pattern of WT1 isoforms in an in vitro model of neuroblastoma consisting in undifferentiated or all-trans retinoic acid (RA) differentiated cells. These latter representing the less malignant phenotype of this tumor. Results have demonstrated that WT1.1-WT1.5, WT1.6-WT1.9, WT1.10 WT1.11-WT1.12 and WT1.13 isoforms are expressed in both groups of cells, but their levels are significantly increased after RA treatment. These data have also been confirmed by immunofluorescence analysis. Moreover, the inhibition of PI3K/Akt and MAPK/ERK, that represent two signalling pathway specifically involved in NB differentiation, induces an overexpression of WT1 isoforms. These data suggest that WT1 isoforms might be involved in differentiation of neuroblastic into mature ganglion cells.
Collapse
Affiliation(s)
- Grazia Maugeri
- Sections of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Agata Grazia D'Amico
- Sections of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy; San Raffaele Telematic University of Rome, Rome, Italy
| | - Daniela Maria Rasà
- Sections of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Rita Reitano
- Sections of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Salvatore Saccone
- Section of Animal Biology, Department of Biological, Geological and Environmental Sciences, University of Catania, Catania, Italy
| | - Concetta Federico
- Section of Animal Biology, Department of Biological, Geological and Environmental Sciences, University of Catania, Catania, Italy
| | - Rosalba Parenti
- Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Gaetano Magro
- Section of Anatomic Pathology, Department of Medical and Surgical Sciences and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", University of Catania, Catania, Italy
| | - Velia D'Agata
- Sections of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| |
Collapse
|
13
|
Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer 2015; 62:1305-16. [PMID: 25810263 PMCID: PMC5132052 DOI: 10.1002/pbc.25501] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Accepted: 01/30/2015] [Indexed: 12/11/2022]
Abstract
Neuroblastoma is the most common extracranial solid tumor in childhood in high-income countries (HIC), where consistent treatment approaches based on clinical and tumor biological risk stratification have steadily improved outcomes. However, in low- and middle- income countries (LMIC), suboptimal diagnosis, risk stratification, and treatment may occur due to limited resources and unavailable infrastructure. The clinical practice guidelines outlined in this manuscript are based on current published evidence and expert opinions. Standard risk stratification and treatment explicitly adapted to graduated resource settings can improve outcomes for children with neuroblastoma by reducing preventable toxic death and relapse.
Collapse
Affiliation(s)
- Nehal S. Parikh
- Department of PediatricsDivision of Hematology‐OncologyConnecticut Children's Medical CenterHartfordConnecticut
| | | | | | - Trijn Israels
- VU University Medical CenterAmsterdamthe Netherlands
| | - Mohammed Khattab
- Department of PaediatricsChildren's Hospital of RabatRabatMorocco
| | - Patricia Alcasabas
- University of the Philippines‐Philippine General HospitalManilaPhilippines
| | - Catherine G. Lam
- Department of Oncology and International Outreach ProgramSt. Jude Children's Research HospitalMemphisTennessee
| | | | - Julie R. Park
- Seattle Children's HospitalUniversity of Washington School of Medicine and Fred Hutchinson Cancer Research CenterSeattleWashington
| | - Wendy B. London
- Harvard Medical SchoolBoston Children's Hospital and Dana Farber Cancer InstituteBostonMaryland
| | - Katherine K. Matthay
- Department of PediatricsUCSF School of Medicine and UCSF Benioff Children's HospitalSan FranciscoCalifornia
| |
Collapse
|
14
|
Kletzel M, Chou PM, Olszewski M, Rademaker AW, Khan S. Expression of Wilms tumor gene in high risk neuroblastoma: complementary marker to tyrosine hydroxylase for detection of minimal residual disease. Transl Pediatr 2015; 4:219-25. [PMID: 26835379 PMCID: PMC4729048 DOI: 10.3978/j.issn.2224-4336.2015.07.01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Neuroblastoma (NB) is an enigmatic tumor that often presents with metastatic disease at diagnosis and it is this aggressive propensity which places it among the deadliest pediatric tumors despite intensive multimodal therapy including hematopoietic stem cell transplantation (HSCT). We have previously demonstrated that Wilms tumor 1 gene (WT1) is a surrogate marker of proliferation in leukemia. To determine the potential association between WT1 and a known marker of NB, tyrosine hydroxylase (TH) in this high risk group of patients. METHODS A total of 141 random samples from 34 patients were obtained, at diagnosis (n=27), during therapy (n=95), in clinical remission (n=13), and at the time of relapse (n=6). Quantitative RT-PCR was used for the evaluation of the level of gene expression using specific primers. RESULTS Although similar gene expressions were demonstrated in both controls when evaluating both genes, significant difference was found at each clinical time point. Furthermore, when comparing patient samples from diagnosis to clinical remission and diagnosis to clinical relapse, individual gene expression varied. WT1 demonstrated significance (P=0.0002) and insignificance (P=0.06) whereas TH remained non-significant (P=0.2, P=0.09) respectively. CONCLUSIONS WT1 gene is indicative of cellular proliferation in NB and for this reason it can be adjuvant to TH for the detection minimal residual disease (MRD).
Collapse
Affiliation(s)
- Morris Kletzel
- 1 Northwestern University Feinberg School of Medicine, Chicago Il, USA ; 2 Lurie Children's Hospital of Chicago Department of Hematology, Oncology and Transplant, Chicago Il, USA ; 3 Stem Cell Transplant Research Laboratory, Chicago Il, USA ; 4 Lurie Children's Hospital of Chicago Department of Pathology, Chicago Il, USA
| | - Pauline M Chou
- 1 Northwestern University Feinberg School of Medicine, Chicago Il, USA ; 2 Lurie Children's Hospital of Chicago Department of Hematology, Oncology and Transplant, Chicago Il, USA ; 3 Stem Cell Transplant Research Laboratory, Chicago Il, USA ; 4 Lurie Children's Hospital of Chicago Department of Pathology, Chicago Il, USA
| | - Marie Olszewski
- 1 Northwestern University Feinberg School of Medicine, Chicago Il, USA ; 2 Lurie Children's Hospital of Chicago Department of Hematology, Oncology and Transplant, Chicago Il, USA ; 3 Stem Cell Transplant Research Laboratory, Chicago Il, USA ; 4 Lurie Children's Hospital of Chicago Department of Pathology, Chicago Il, USA
| | - Alfred W Rademaker
- 1 Northwestern University Feinberg School of Medicine, Chicago Il, USA ; 2 Lurie Children's Hospital of Chicago Department of Hematology, Oncology and Transplant, Chicago Il, USA ; 3 Stem Cell Transplant Research Laboratory, Chicago Il, USA ; 4 Lurie Children's Hospital of Chicago Department of Pathology, Chicago Il, USA
| | - Sana Khan
- 1 Northwestern University Feinberg School of Medicine, Chicago Il, USA ; 2 Lurie Children's Hospital of Chicago Department of Hematology, Oncology and Transplant, Chicago Il, USA ; 3 Stem Cell Transplant Research Laboratory, Chicago Il, USA ; 4 Lurie Children's Hospital of Chicago Department of Pathology, Chicago Il, USA
| |
Collapse
|
15
|
WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues. J Cell Commun Signal 2015; 9:347-52. [PMID: 26123754 DOI: 10.1007/s12079-015-0293-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Accepted: 04/16/2015] [Indexed: 11/27/2022] Open
Abstract
Dupuytren's disease (DD) is a fibroproliferative and contractile fibrosis of the palmar fascia that, like all other heritable fibroses, is currently incurable. While DD is invariably benign, it exhibits some molecular similarities to malignant tumours, including increased levels of ß-catenin, onco-fetal fibronectin, periostin and insulin-like growth factor (IGF)-II. To gain additional insights into the pathogenesis of DD, we have assessed the expression of WT1, encoding Wilm's tumour 1, an established tumour biomarker that is syntenic with IGF2, the gene encoding IGF-II in humans. We found that WT1 expression is robustly and consistently up regulated in primary fibroblasts derived from the fibrotic palmar fascia of patients with DD (DD cells), whereas syngeneic fibroblasts derived from the macroscopically unaffected palmar fascia in these patients and allogeneic fibroblasts derived from normal palmar fascia exhibited very low or undetectable WT1 transcript levels. WT1 immunoreactivity was evident in a subset of cells in the fibrotic palmar fascia of patients with DD, but not in macroscopically unaffected palmar fascia. These findings identify WT1 expression as a novel biomarker of fibrotic palmar fascia and are consistent with the hypothesis that the pathogeneses of DD and malignant tumours have molecular similarities.
Collapse
|
16
|
Magro G, Longo FR, Angelico G, Spadola S, Amore FF, Salvatorelli L. Immunohistochemistry as potential diagnostic pitfall in the most common solid tumors of children and adolescents. Acta Histochem 2015; 117:397-414. [PMID: 25881477 DOI: 10.1016/j.acthis.2015.03.011] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Revised: 03/19/2015] [Accepted: 03/25/2015] [Indexed: 12/11/2022]
Abstract
Making a correct diagnosis when dealing with a small round blue cell tumor (SRBCT) of children and adolescents may be relatively straightforward if the tumor arises in the typical clinical setting and the classic pathologic features are all recognizable. However it is widely known that diagnostic difficulties may arise because of: (i) many tumors share overlapping morphological and/or immunohistochemical features; (ii) considerable clinical, pathologic, and immunohistochemical variations do exist; (iii) the increasing use of small biopsies in daily practice makes the diagnosis of these neoplasms more challenging. Accordingly, immunohistochemical analyses are currently mandatory in establishing the correct diagnosis. In this regard there is the need to identify more sensitive and specific immunomarkers useful in the distinction of the several tumor entities. Over the last decades, several markers, such as CD99, WT1 protein, desmin, myogenin, NB84, and INI1 have been identified, providing a considerable help in recognition of the most common solid tumors (ESW/pPNET, rhabdomyosarcoma, neuroblastoma, Wilms' tumor, desmoplastic small round cell tumor; malignant rhabdoid tumor) in children and adolescents. However, at the same time, their unusual, unexpected expression can result in a misinterpretation of the immunohistochemical results, especially by pathologists who are not familiar with oncologic pediatric pathology. Therefore the present review focuses on the potential immunohistochemical pitfalls which should be kept in mind by pathologists to prevent diagnostic errors when dealing with SRBCTs.
Collapse
Affiliation(s)
- Gaetano Magro
- Department of Medical and Surgical Sciences and Advanced Technologies, "G.F. Ingrassia", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy.
| | - Francesca Romana Longo
- Department of Medical and Surgical Sciences and Advanced Technologies, "G.F. Ingrassia", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy
| | - Giuseppe Angelico
- Department of Medical and Surgical Sciences and Advanced Technologies, "G.F. Ingrassia", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy
| | - Saveria Spadola
- Department of Medical and Surgical Sciences and Advanced Technologies, "G.F. Ingrassia", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy
| | - Flavia Francesca Amore
- Department of Medical and Surgical Sciences and Advanced Technologies, "G.F. Ingrassia", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy
| | - Lucia Salvatorelli
- Department of Medical and Surgical Sciences and Advanced Technologies, "G.F. Ingrassia", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy
| |
Collapse
|
17
|
Magro G, Salvatorelli L, Puzzo L, Musumeci G, Bisceglia M, Parenti R. Oncofetal expression of Wilms' tumor 1 (WT1) protein in human fetal, adult and neoplastic skeletal muscle tissues. Acta Histochem 2015; 117:492-504. [PMID: 25800978 DOI: 10.1016/j.acthis.2015.02.012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2014] [Revised: 02/10/2015] [Accepted: 02/21/2015] [Indexed: 12/12/2022]
Abstract
There is increasing evidence that WT1 protein expression is found not only at nuclear, but also at cytoplasmic, level in several developing and neoplastic tissues. In order to better understand the possible role of WT1 protein in human skeletal myogenesis and oncogenesis of rhabdomyosarcoma, we assessed immunohistochemically its comparative expression in a large series of human developing, adult and neoplastic skeletal muscle tissues. The present study shows that WT1 protein is developmentally expressed in the cytoplasm of human myoblasts from the 6 weeks of gestational age. This expression was maintained in the myotubes of developing muscles of the trunk, head, neck, and extremities, while it was down-regulated in fetal skeletal fibers from 20 weeks of gestational age as well as in adult normal skeletal muscle. Notably, WT1 immunostaining disappeared from rhabdomyomas, whereas it was strongly and diffusely re-expressed in all cases (27/27) of embryonal and alveolar rhabdomyosarcoma. The comparative evaluation of the immunohistochemical findings revealed that WT1 cytoplasmic expression in rhabdomyosarcoma may represent an ontogenetic reversal, and this nuclear transcription factor can also be considered an oncofetal protein which can be exploitable as an additional, highly sensitive immunomarker, together with desmin, myogenin and MyoD1, of this tumor. Moreover, our observations support the rationale for the use of WT1 protein-based target therapy in high risk rhabdomyosarcomas in children and adolescents.
Collapse
|
18
|
Salvatorelli L, Parenti R, Leone G, Musumeci G, Vasquez E, Magro G. Wilms tumor 1 (WT1) protein: Diagnostic utility in pediatric tumors. Acta Histochem 2015; 117:367-78. [PMID: 25881478 DOI: 10.1016/j.acthis.2015.03.010] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Revised: 03/15/2015] [Accepted: 03/20/2015] [Indexed: 02/05/2023]
Abstract
Despite Wilms tumor 1 (WT1) protein was originally considered as a specific immunomarker of Wilms tumor, with the increasing use of immunohistochemistry, there is evidence that other tumors may share WT1 protein expression. This review focuses on the immunohistochemical profile of WT1 protein in the most common malignant tumors of children and adolescents. The variable expression and distribution patterns (nuclear vs cytoplasmic) in the different tumors, dependent on the antibodies used (anti-C or N-terminus WT1 protein), will be emphasized by providing explicative illustrations. Potential diagnostic pitfalls from unexpected WT1 protein expression in some tumors will be discussed in order to avoid diagnostic errors, especially when dealing with small biopsies.
Collapse
Affiliation(s)
- Lucia Salvatorelli
- Department of Medical and Surgical Sciences and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy.
| | - Rosalba Parenti
- Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, Catania, Italy
| | - Giorgia Leone
- Anatomic Pathology, Hospital of Sondrio, Sondrio, Italy
| | - Giuseppe Musumeci
- Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, Catania, Italy
| | - Enrico Vasquez
- Department of Medical and Surgical Sciences and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy
| | - Gaetano Magro
- Department of Medical and Surgical Sciences and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Anatomic Pathology Section, University of Catania, Catania, Italy
| |
Collapse
|
19
|
Alomari AK, Glusac EJ, McNiff JM. p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma. J Cutan Pathol 2014; 41:839-45. [PMID: 25263848 DOI: 10.1111/cup.12388] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Revised: 07/24/2014] [Accepted: 09/02/2014] [Indexed: 11/29/2022]
Abstract
BACKGROUND Poorly differentiated squamous cell carcinoma (SCC) of the skin may pose a diagnostic challenge for pathologists. p40 is a recently introduced antibody that recognizes specific p63 protein isoforms and has shown superior results labeling non-cutaneous SCC. We hypothesize that p40 may improve diagnostic accuracy of poorly differentiated SCC. METHODS Twelve cases of poorly differentiated SCC were stained with p63, p40 and cytokeratin MNF116. Control cases included nine atypical fibroxanthoma (AFX), five cutaneous leiomyosarcoma (LMS) and three giant cell tumors of soft tissue (GCTST). RESULTS All 12 cases labeled with p63 and p40 and 11/12 were positive with MNF116. Whereas p40 labeled fewer cells, it showed exclusive nuclear staining, with no staining of cytoplasm or of background cells, in contrast to p63. Six of nine AFX and 2 of 3 GCTST showed scattered nuclear staining with p63 but were negative with p40. Additionally, one LMS showed focal staining with MNF116 but was negative with p40. CONCLUSION For the diagnosis of cutaneous poorly differentiated SCC, p40 appears equally sensitive to MNF116 and p63. While labeling fewer cells, p40 labels without confounding staining of tumor cytoplasm or background cells. More importantly, p40 appears to be more specific for SCC than p63 and MNF116, each of which occasionally labels non-squamous tumors.
Collapse
Affiliation(s)
- Ahmed K Alomari
- Department of Pathology, Yale University, School of Medicine, New Haven, CT, USA
| | | | | |
Collapse
|
20
|
Liang L, Tatevian N, Bhattacharjee M, Tsao K, Hicks J. Desmoplastic small round cell tumor with atypical immunohistochemical profile and rhabdoid-like differentiation. World J Clin Cases 2014; 2:367-372. [PMID: 25133149 PMCID: PMC4133428 DOI: 10.12998/wjcc.v2.i8.367] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2014] [Revised: 05/03/2014] [Accepted: 06/11/2014] [Indexed: 02/05/2023] Open
Abstract
Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive malignant neoplasm of unknown origin, and is comprised of small round cells with a characteristic desmoplastic stroma. DSRCT typically expresses epithelial, mesenchymal and neural markers simultaneously. We describe a case of DSRCT with an atypical immunohistochemical profile and rhabdoid-like tumor cells on electron microscopy. In the present case, the neoplastic cells were positive only for vimentin, desmin (cytoplasmic membranous pattern) and CD56, and negative for smooth muscle actin, synaptophysin, CD117, CD45, myogenin, CAM5.2, pancytokeratin, WT1, EMA, CD99, neurofilament, CD34 and p53. Ki67 showed a low proliferative activity. Electron microscopy showed focal rhabdoid differentiation. However, INI-1 (SNF-5/BAF47) demonstrated preservation of nuclear positivity in the neoplastic cells. Cytogenetic studies showed translocation t(11;22)(p13;q12) confirming an EWSR1-WT1 translocation characteristic for DSRCT, and t(1;15)(q11;p11.2) of unknown significance. This case is a diagnostic challenge because of atypical immunohistochemical profile and cytogenetic study is crucial in rendering the correct diagnosis.
Collapse
|
21
|
Abstract
Tissue diagnosis of small round cell tumors relies heavily on immunohistochemical staining. Two of the small round cell tumors, namely neuroblastoma and primitive neuroectodermal tumor, have considerable morphologic overlap. Many studies suggest that CD99 positivity virtually excludes the diagnosis of neuroblastoma. We report a case of poorly differentiated neuroblastoma in which aberrant CD99 positivity led to diagnostic dilemma.
Collapse
Affiliation(s)
- Gagandeep Kaur
- Department of Pathology, Sir Ganga Ram Hospital, New Delhi, India
| | | | | |
Collapse
|
22
|
Juxtarenal Wilms Tumor in an Adolescent. Urology 2012; 80:922-4. [DOI: 10.1016/j.urology.2012.06.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2012] [Revised: 06/05/2012] [Accepted: 06/12/2012] [Indexed: 01/05/2023]
|
23
|
PHOX2B immunolabeling: a novel tool for the diagnosis of undifferentiated neuroblastomas among childhood small round blue-cell tumors. Am J Surg Pathol 2012; 36:1141-9. [PMID: 22790854 DOI: 10.1097/pas.0b013e31825a6895] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Peripheral neuroblastic tumors are the most commonly occurring extracranial tumors in children. Although a reliable diagnosis is achievable in the majority of cases, diagnosis of a minority of peripheral neuroblastic tumor cases (especially undifferentiated neuroblastoma) poses a challenge compared with that of other pediatric small round blue-cell tumors. A panel of immunohistochemical markers and fusion transcripts is available for the diagnosis of such tumors, but the markers for neuroblastoma lack specificity and sensitivity. As the transcription factor PHOX2B is highly specific for the peripheral autonomic nervous system from which peripheral neuroblastic tumors are derived, we have assessed PHOX2B immunolabeling as a diagnostic tool in pediatric small round blue-cell tumors. We observed PHOX2B expression in all peripheral neuroblastic tumors, paragangliomas, and pheochromocytomas tested but in no other pediatric tumors among the 388 cases studied by expression microarray and the 109 cases studied by immunohistochemical analysis. We then assessed the results of PHOX2B immunohistochemistry in 12 cases of undifferentiated pediatric neoplasms: PHOX2B was expressed in 6/6 undifferentiated neuroblastomas and in no other small round blue-cell tumors. Finally, we showed that PHOX2B immunohistochemical analysis improves the diagnosis of undifferentiated neuroblastoma with high specificity and sensitivity.
Collapse
|
24
|
Ewing sarcoma family of tumours: unusual histological variants and immunophenotypic characteristics. ACTA ACUST UNITED AC 2012. [DOI: 10.1016/j.mpdhp.2012.06.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
25
|
Abstract
Immunohistochemistry in soft tissue tumours, and especially sarcomas, is used to identify differentiation in the neoplastic cells. In some cases, specific antigens are expressed; however, an initial panel of antibodies is often required in order to establish the broad lineage, with a subsequent, more focused, panel to allow classification. Immunohistochemical evaluation must be employed with the clinical picture, the morphology, and, when necessary, other ancillary techniques such as molecular genetics and cytogenetics. Whereas some diagnoses are evident on morphology, many soft tissue neoplasms are seen microscopically as spindle cell, epithelioid cell, small round cell or pleomorphic tumours that need to be further characterized. This article reviews selected applications of immunohistochemistry in the diagnosis of each of the principal morphological groups, concentrating on areas of most use in daily practice.
Collapse
Affiliation(s)
- Cyril Fisher
- Department of Histopathology, Royal Marsden Hospital, London, UK.
| |
Collapse
|
26
|
Abstract
The Ewing sarcoma family of tumors (ESFT) consists of a group of tumors characterized by morphologically similar round-cell neoplasm and by the presence of a common chromosomal translocation. Although rare, such tumors constitute the third most frequent primary sarcoma of bone after osteosarcoma and chondrosarcoma. ESFT most commonly affects young children and adolescents. Because most patients with clinically apparent localized disease at diagnosis may also have occult metastatic (ie, systemic) disease, multidrug chemotherapy as well as local disease control with surgery and/or radiation therapy are indicated for all patients. Despite marked improvements in survival during the past 40 years for patients with localized disease, lesser improvements have been seen in patients with metastatic or recurrent disease. A better understanding of the complex biology of ESFT may lead to the successful development of biologically targeted therapies. As the regulatory pathways responsible for transformation, growth, and metastasis of ESFT become more refined, the number of potential therapeutic targets will expand.
Collapse
|
27
|
Yu Z, Parham DM. Paediatric soft tissue tumours: from histology to molecular diagnosis. ACTA ACUST UNITED AC 2009. [DOI: 10.1016/j.mpdhp.2009.08.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
28
|
Garrido-Ruiz MC, Rodriguez-Pinilla SM, Pérez-Gómez B, Rodriguez-Peralto JL. WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis. J Cutan Pathol 2009; 37:542-8. [PMID: 19638168 DOI: 10.1111/j.1600-0560.2009.01379.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
BACKGROUND WT1, first recognized as a tumor suppressor gene involved in the development of Wilms' tumor, may have apparently contradictory findings and functions. As WT1 has been identified as a molecular target for cancer immunotherapy, immunodetection of WT1 in tumor cells has become an essential step in cancer studies. METHODS We compare the expression of this protein among different types of melanocytic nevi and among stages in primary melanoma progression. Tissue microarrays containing normal tissues and 271 primary melanocytic lesion samples (163 primary melanomas and 108 nevi) were studied by immunohistochemistry using monoclonal antibody against WT1. RESULTS AND DISCUSSION The present study shows these: 1. WT1 protein is predominantly expressed in the cytoplasm of the neoplastic cells. 2. A higher rate of WT1 staining in melanocytic nevi against melanomas has been observed. 3. WT1 expression is increased in advanced stages of melanoma progression: a significant (p < 0.05) increase of expression of WT1 was detected in vertical cases 46.5% vs. radial cases 16.0%, in high levels of Clark (IV, V) 57.4% vs. low levels (I, II, III) 33.0% and when comparing depth of invasion within thickness subgroups. 4. Finally, this study establishes an association of WT1 protein expression with shorter overall survival in melanoma.
Collapse
Affiliation(s)
- M C Garrido-Ruiz
- Dpto. de Anatomía Patológica, Hospital Universitario12 de Octubre, Avda de Córdoba s/n, 28041 Madrid, Spain
| | | | | | | |
Collapse
|
29
|
Bridge JA. Contribution of Cytogenetics to the Management of Poorly Differentiated Sarcomas. Ultrastruct Pathol 2009; 32:63-71. [DOI: 10.1080/01913120801897141] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
30
|
WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 2009; 23:1634-42. [PMID: 19357702 DOI: 10.1038/leu.2009.70] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The Wilms tumor antigen, WT1, is expressed at high levels in various types of leukemia and solid tumors, including lung, breast, colon cancer and soft tissue sarcomas. The WT1 protein has been found to be highly immunogenic, and spontaneous humoral and cytotoxic T-cell responses have been detected in patients suffering from leukemia. Furthermore, major histocompatibility complexes class I- and II-restricted WT1 peptide epitopes have been shown to elicit immune responses in patients with WT1-expressing tumors. As a consequence, WT1 has become an attractive target for anticancer immunotherapy. In this study, we investigated the feasibility of generating WT1-specific T cells for adoptive immunotherapy after allogeneic stem cell transplantation. We analyzed the incidence of T cells specific for WT1 peptide epitopes in cancer patients and healthy volunteers. It is noted that we could generate WT1-specific responses in nine of ten healthy volunteer donors and established T-cell clones specific for two WT1-derived peptide epitopes. These in vitro expanded WT1-specific T cells effectively lysed WT1-expressing tumor cell lines, indicating the potential clinical impact of ex vivo expanded donor-derived WT1-specific T cells for adoptive immunotherapy after allogeneic stem cell transplantation.
Collapse
|
31
|
|
32
|
Murphy AJ, Bishop K, Pereira C, Chilton-MacNeill S, Ho M, Zielenska M, Thorner PS. A new molecular variant of desmoplastic small round cell tumor: significance of WT1 immunostaining in this entity. Hum Pathol 2008; 39:1763-70. [DOI: 10.1016/j.humpath.2008.04.019] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2007] [Revised: 04/12/2008] [Accepted: 04/14/2008] [Indexed: 11/26/2022]
|
33
|
Pohar-Marinšek Ž. Difficulties in diagnosing small round cell tumours of childhood from fine needle aspiration cytology samples. Cytopathology 2008; 19:67-79. [DOI: 10.1111/j.1365-2303.2008.00555.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
34
|
|
35
|
|
36
|
Wick MR. Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors. Ann Diagn Pathol 2008; 12:72-84. [DOI: 10.1016/j.anndiagpath.2007.10.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Al-Adnani M, Williams S, Anderson J, Ashworth M, Malone M, Sebire NJ. Immunohistochemical nuclear positivity for WT1 in childhood acute myeloid leukemia. Fetal Pediatr Pathol 2007; 26:193-7. [PMID: 18075834 DOI: 10.1080/15513810701696957] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Several studies have reported previously that acute myeloid leukemia (AML) may express WT1 detected by RT-PCR and/or Northern blotting. The diagnostic utility of WT1 expression in AML using immunohistochemistry has not been reported previously. Paraffin-embedded tissue sections from 55 AML, 12 acute lymphoblastic leukemia (ALL), and 10 normal bone marrow specimens were immunostained for WT1 (anti-N terminus antibody). 22/55 AML cases (40%) demonstrated nuclear immunopositivity for WT1, including 20/47 bone marrow trephines and 2/4 granulocytic sarcomas. All the ALL and normal bone marrow specimens were negative. A significant proportion of AML expresses nuclear immunostaining for WT1, a finding that has only been described previously in Wilms' tumor and desmoplastic small round cell tumor. This finding is important for the correct interpretation of immunohistochemical findings in the diagnosis of "small round cell" tumors of childhood, especially in cases of extramedullary deposits of AML, in which traditional myeloid markers may be negative.
Collapse
Affiliation(s)
- Mudner Al-Adnani
- Department of Paediatric Histopathology, Camelia Botnar Laboratories, Great Ormond Street Hospital, London, United Kingdom
| | | | | | | | | | | |
Collapse
|
38
|
Antoine M. [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment]. REVUE DE PNEUMOLOGIE CLINIQUE 2007; 63:183-92. [PMID: 17675942 DOI: 10.1016/s0761-8417(07)90123-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Immunohistochemistry (IHC) has become an indispensable tool in pathology. For proper interpretation, results must be read with knowledge of the diagnostic, clinical, and morphological circumstances. We detail here the contribution of IHC to the classification of lung cancer: small-cell lung cancer and other neuroendocrine tumors, basaloid carcinoma, large-cell carcinoma. Using IHC techniques, pathologists can now determine with certainty that an intrathoracic adenocarcinoma is primary or secondary. The distinction is less clear for large-cell carcinoma or squamous-cell carcinoma, or for tumors with a pleural or mediastinal presentation. IHC is also useful as a diagnostic aid for rare entities: carcinomas with an unusual morphology (alpha-fetoproetin secretors or beta-HCG secretors), melanomas, lymphomas, sarcomas. By demonstrating the presence of carcinomatous cells within the neighboring structures (pleura) or lymph nodes, IHC contributes to lung cancer staging, particularly when there are few of these elements morphologically difficult to distinguish. Finally, IHC contributes to prognosis (proliferation markers, differentiation markers) or prediction of therapeutic response (chemotherapy or targeted therapies). IHC studies may also be requested in a forensic setting, for example to demonstrate that the lung cancer observed in a patient exposed to asbestosis is primary. In light of these different situations, a wide panel of antibodies is required. Other morphological techniques such as hybridization in situ or molecular biology techniques will further complete the histological diagnosis in the future.
Collapse
Affiliation(s)
- M Antoine
- Service d'Anatomie Pathologique, Hôpital Tenon, AP-HP, 4 rue de la Chine, 75970 Paris Cedex 20.
| |
Collapse
|
39
|
Wang LL, Perlman EJ, Vujanic GM, Zuppan C, Brundler MA, Cheung CRLH, Calicchio ML, Dubois S, Cendron M, Murata-Collins JL, Wenger GD, Strzelecki D, Barr FG, Collins T, Perez-Atayde AR, Kozakewich H. Desmoplastic Small Round Cell Tumor of the Kidney in Childhood. Am J Surg Pathol 2007; 31:576-84. [PMID: 17414105 DOI: 10.1097/01.pas.0000213432.14740.14] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Desmoplastic small round cell tumor (DSRCT) is a rare malignant tumor that generally manifests as abdominal paraserosal masses and affects mainly male adolescents and young adults. When presenting within visceral organs, the diagnosis of DSRCT poses significant difficulties. METHODOLOGY Four primary renal DSRCT in children diagnosed during a 3-year period are the basis of this report. The medical records and pathologic material were reviewed, including immunohistochemical, ultrastructural, and cytogenetic/molecular studies. RESULTS The age at presentation was 6 to 8 years, and all children presented with a left renal mass. The tumors measured 3.7 to 13.4 cm and consisted of nests, cords, or sheets of small undifferentiated cells with foci of necrosis and calcification. Desmoplasia was not seen. Tumor cells were immunopositive for vimentin, WT-1 (monoclonal and polyclonal), desmin, cytokeratin, and epithelial membrane antigen. A distinct paranuclear dotlike pattern was observed with vimentin and desmin. Tumor cells possessed rare or focal immunoreactivity for platelet derived growth factor-A and transforming growth factor-beta3, which have been implicated in the pathogenesis of desmoplasia in DSRCT. The EWS-WT1 t(11;22)(p13;q12) translocation was demonstrated in all 4 tumors by fluorescence in situ hybridization and/or reverse transcription-polymerase chain reaction. CONCLUSIONS DSRCT should be considered in the differential diagnosis of renal tumors composed of small round cells. Undifferentiated morphology and lack of desmoplasia contribute to the difficulty in its recognition. Ancillary studies such as immunohistochemistry may suggest the diagnosis, but cytogenetic and molecular genetic studies are required for confirmation.
Collapse
Affiliation(s)
- Larry L Wang
- Department of Pathology, Children's Hospital Boston, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
George S, Vaideeswar P, Pandit S, Kane S, Khandeparkar J. Malignant small round cell tumor of the heart: a diagnostic dilemma. Cardiovasc Pathol 2007; 16:56-8. [PMID: 17218216 DOI: 10.1016/j.carpath.2006.09.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2006] [Revised: 08/05/2006] [Accepted: 09/01/2006] [Indexed: 11/18/2022] Open
Abstract
We report a rare malignant small round cell tumor of the heart in a 26-year-old woman. She had been symptomatic 15 days after vaginal delivery. Immunohistochemistry revealed divergent differentiation; hence, the tumor was designated as desmoplastic small round cell tumor. This is the first report of such a tumor in the heart.
Collapse
Affiliation(s)
- Sophia George
- Department of Pathology (Cardiovascular and Thoracic Division), Seth G. S. Medical College, Parel, Mumbai 400 012, India
| | | | | | | | | |
Collapse
|
41
|
Nakatsuka SI, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19:804-14. [PMID: 16547468 DOI: 10.1038/modpathol.3800588] [Citation(s) in RCA: 219] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
WT1 was first identified as a tumor suppressor involved in the development of Wilms' tumor. Recently, oncogenic properties of WT1 have been demonstrated in various hematological malignancies and solid tumors. Because WT1 has been identified as a molecular target for cancer immunotherapy, immunohistochemical detection of WT1 in tumor cells has become an essential part of routine practice. In the present study, the expression of WT1 was examined in 494 cases of human cancers, including tumors of the gastrointestinal and pancreatobiliary system, urinary tract, male and female genital organs, breast, lung, brain, skin, soft tissues and bone by immunohistochemistry using polyclonal (C-19) and monoclonal (6F-H2) antibodies against WT1 protein. Staining for C-19 and 6F-H2 was found in 35-100 and 5-88% of the cases of each kind of tumor, respectively. WT1-positive tumors included tumor of the stomach, prostate, and biliary and urinary systems, and malignant melanomas. A majority of the positive cases showed diffuse or granular staining in the cytoplasm, whereas ovarian tumors and desmoplastic small round cell tumors frequently showed nuclear staining. Glioblastomas, some of soft tissue sarcomas, osteosarcomas, and malignant melanomas of the skin showed extremely strong cytoplasmic staining as compared with other tumors. Western blot analysis showed that WT1 protein was predominantly expressed in the cytoplasm of the tumor cells in two cases of lung adenocarcinoma, supporting the intracytoplasmic staining for WT1 using immunohistochemistry. Immunohistochemical detection with routinely processed histologic sections could provide meaningful information on the expression of WT1 in cancer cells.
Collapse
Affiliation(s)
- Shin-ichi Nakatsuka
- Department of Clinical Laboratory, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol 2006; 19:659-68. [PMID: 16528378 DOI: 10.1038/modpathol.3800569] [Citation(s) in RCA: 139] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
As a result of overlapping morphologic and immunohistochemical features, it can be difficult to distinguish synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma/primitive neuroectodermal tumor in core biopsies. To analyze and compare immunohistochemical profiles, we stained tissue microarrays of 23 synovial sarcomas, 23 malignant peripheral nerve sheath tumors, and 27 Ewing sarcomas with 22 antibodies potentially useful in the differential diagnosis, and analyzed the data with cluster analysis. Stain intensity was scored as none, weak, or strong. For CD99, tumors with membranous accentuation were independently categorized. Cluster analysis sorted five groups, with like tumors clustering together. Synovial sarcoma clustered into two groups: one cytokeratin and EMA positive (n = 11), the other mostly cytokeratin negative, EMA positive, bcl-2 positive and mostly CD56 positive (n = 9). Malignant peripheral nerve sheath tumor clustered into two groups: one S100 positive, with nestin and NGFR positivity in most (n = 10), the other mostly S100 negative, and variably but mostly weakly positive for nestin and NGFR (n = 11). Ewing sarcomas clustered into a single group driven by membranous CD99 staining. Thirteen cases failed to cluster (outliers), while three Ewing sarcomas clustered into groups of other tumor types. Paired antibodies for each tumor type determined by visual assessment of cluster analysis data and statistical calculations of specificity, sensitivity, and predictive values showed that EMA/CK7 for synovial sarcoma, nestin/S100 for malignant peripheral nerve sheath tumor, and membranous CD99/Fli-1 for Ewing sarcoma yielded high specificity and positive predictive values. Cluster analysis also highlighted aberrant staining reactions and diagnostic pitfalls in these tumors. Hierarchical cluster analysis is an effective method for analyzing high-volume immunohistochemical data.
Collapse
Affiliation(s)
- Stephen H Olsen
- Department of Pathology, The University of Michigan Medical School, Ann Arbor, MI 48109-0054, USA
| | | | | |
Collapse
|
43
|
Hendershot E. Treatment approaches for metastatic Ewing's sarcoma: a review of the literature. J Pediatr Oncol Nurs 2006; 22:339-52. [PMID: 16216896 DOI: 10.1177/1043454205279300] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The Ewing's sarcoma family of tumors (ESFT) is an aggressive group of neoplasms that represent approximately 3% of all pediatric malignancies. The overall survival rates in patients with localized disease are approaching 75%. The outcome for the 25% of patients who present with metastatic disease, however, remains poor, with long-term survival rates of less than 30%. This review will explore the natural history of ESFT including clinical presentation, molecular pathology, and high-risk features of the disease. Outcomes of metastatic treatment protocols to date will be examined as well as the rationale for current and future therapies. Nursing considerations in caring for patients with metastatic ESFT will be discussed. A case scenario will be reviewed to highlight treatment and supportive care issues in the management of the disease. Cancer therapy in general is becoming more complex; treatment approaches involve different ways of targeting tumor cells. It is crucial that nurses caring for these patients understand the rationale behind treatment strategies so that appropriate patient education and support may be given.
Collapse
Affiliation(s)
- Eleanor Hendershot
- Solid Tumor Program in the Division of Hematology/Oncology at Hospital for Sick Children, Toronto, Ontario, Canada.
| |
Collapse
|